There are three subtypes of the peroxisome proliferator-activated receptor (PPAR) family (α, γ and β/δ), and synthetic ligands for PPARα (fibrates) and PPARγ (Thiazolidinediones, TZDs) are currently prescribed for the respective management of T2D due to their ability to ameliorate hyperglycaemia by improving glucose metabolism of insulin target tissues [79]. The gene discussed is PPARA; the disease is Hyperglycemia.